May 4, 2020
First Annual National Mechanical Dry Eye Day is May 19, 2020
Inaugural day to bring awareness to Mechanical Dry Eye, one of the most overlooked and often misdiagnosed age-related eye conditions
Miami, FL – May 4, 2020 – BioTissue, Inc., a TissueTech, Inc. company and leader in the clinical application of human birth tissue products for ocular surface disease and disorders, has announced that the first-ever National Mechanical Dry Eye (MDE) Day will be recognized on May 19, 2020. This official holiday has been designated by the National Day Archives on the National Day Registry™ and will take place annually on May 19th.
BioTissue has been on the forefront of advancing scientific research in ocular surface disease for more than 20 years, with the company’s co-founder and Chief Technology Officer Scheffer C.G. Tseng, MD, PhD identifying and pioneering the successful diagnosis and treatment of Mechanical Dry Eye with the use of the company’s proprietary cryopreserved amniotic membrane product, AmnioGraft®. Mechanical Dry Eye is an age-related disorder often found in individuals over 60. This condition is also known as Conjunctivochalsis (CCh). It can be misdiagnosed or overlooked because the symptoms, including dryness, redness, eye pain, blurry vision and excessive tearing, are similar to other types of ocular surface diseases. In fact, in a clinical study conducted by the National Institutes of Health (NIH), the majority of CCh patients were diagnosed with more common ocular surface conditions, such as dry eye, blepharitis, or allergic eye disease, prior to the correct diagnosis.1.
“Conjunctivochalsis is the presence of redundant folds of loose conjunctiva– the clear, thin membrane that covers part of the front surface of the eye and the inner surface of the eyelids — that protrude over the lower eyelid margin and disturb the tear reservoir. In normal eyes, tears are spread over the eye when the patient blinks, ” said Dr. Tseng. “In MDE, excess folds of loose and wrinkled conjunctiva can block this tear reservoir and prevent tear retention and tear spreading. This is what causes dry eyes.”
BioTissue is encouraging people to learn more about MDE on #MDEMondays by visiting BioTissue’s Facebook,LinkedIn, Instagram and Twitter pages. People can also learn how MDE is different from conventional dry eye, its symptoms, and effective treatment options on BioTissue’s DiscoverMDE.com website.
About BioTissue, Inc.
BioTissue, Inc., a TissueTech, Inc. company, is the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface. Established in 1997, BioTissue serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, pterygium, and dry eye. Connect with BioTissue on our Physician’s Portal (for healthcare professionals only), Website, Facebook,LinkedIn, and Twitter.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., pioneered the development and clinical application of human birth tissue-based products. Founded in 1997, BioTissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its products and platform technology. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA to act as an anti-inflammatory anti-scarring and anti-angiogenic agent. Learn more at https://biotissue.com/.
